Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Bing Oei"'
Autor:
Dirk De Ruysscher, Frank J. Lagerwaard, Joost J.C. Verhoeff, E. Dieleman, Dianne Hartgerink, Coen W. Hurkmans, Philippe Lambin, Peter-Paul van der Toorn, Ruud Wiggenraad, Bing Oei, A. Bruynzeel, Annemarie T. Swaak-Kragten, J. Zindler, A. Swinnen, Daniëlle B.P. Eekers, Lieneke van Veelen
Publikováno v:
Neuro-oncology advances, 3(1):vdab021. Oxford University Press
Neuro-oncology Advances
Neuro-Oncology Advances, 3(1):vdab021. Oxford University Press
Hartgerink, D, Bruynzeel, A, Eekers, D, Swinnen, A, Hurkmans, C, Wiggenraad, R, Swaak-Kragten, A, Dieleman, E, van der Toorn, P-P, Oei, B, van Veelen, L, Verhoeff, J, Lagerwaard, F, de Ruysscher, D, Lambin, P & Zindler, J 2021, ' A Dutch phase III randomized multicenter trial : Whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases ', Neuro-oncology advances, vol. 3, no. 1, vdab021 . https://doi.org/10.1093/noajnl/vdab021
Neuro-oncology Advances
Neuro-Oncology Advances, 3(1):vdab021. Oxford University Press
Hartgerink, D, Bruynzeel, A, Eekers, D, Swinnen, A, Hurkmans, C, Wiggenraad, R, Swaak-Kragten, A, Dieleman, E, van der Toorn, P-P, Oei, B, van Veelen, L, Verhoeff, J, Lagerwaard, F, de Ruysscher, D, Lambin, P & Zindler, J 2021, ' A Dutch phase III randomized multicenter trial : Whole brain radiotherapy versus stereotactic radiotherapy for 4-10 brain metastases ', Neuro-oncology advances, vol. 3, no. 1, vdab021 . https://doi.org/10.1093/noajnl/vdab021
Background The clinical value of whole brain radiotherapy (WBRT) for brain metastases (BM) is a matter of debate due to the significant side effects involved. Stereotactic radiosurgery (SRS) is an attractive alternative treatment option that may avoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b54715f54c43def81baf7058e2a2e23
https://research.vumc.nl/en/publications/85156bb5-970b-4007-bd4b-110b6cb11ac2
https://research.vumc.nl/en/publications/85156bb5-970b-4007-bd4b-110b6cb11ac2
Autor:
P. Lambin, Annemarie T. Swaak-Kragten, Frank J. Lagerwaard, P.P. van der Toorn, A. Swinnen, Joost J.C. Verhoeff, L. van Veelen, Daniëlle B.P. Eekers, A. Bruynzeel, Dianne Hartgerink, E. Dieleman, Ruud Wiggenraad, Dirk De Ruysscher, Jaap D. Zindler, Bing Oei, Coen W. Hurkmans
Publikováno v:
SSRN Electronic Journal.
Background: Since publication of the QUARTZ trial, the clinical value of whole brain radiotherapy (WBRT) for brain metastases is a matter of debate due to significant side effects. In order to avoid these side effects and to improve local tumor contr
Autor:
Peter Paul van der Toorn, Jaap D. Zindler, Rosemarijne Beumer, Bing Oei, Esther G.C. Troost, M. Essers, Arthur Jochems, A. Swinnen, Ralph T.H. Leijenaar, Daniëlle B.P. Eekers, Geert Bosmans, Inge Compter, Coen W. Hurkmans, Philippe Lambin, Anna M.E. Bruynzeel, Frank J. Lagerwaard
Publikováno v:
Zindler, J D, Jochems, A, Lagerwaard, F J, Beumer, R, Troost, E G C, Eekers, D B P, Compter, I, van der Toorn, P P, Essers, M, Oei, B, Hurkmans, C W, Bruynzeel, A M E, Bosmans, G, Swinnen, A, Leijenaar, R T H & Lambin, P 2017, ' Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer : Two externally validated nomograms ', Radiotherapy and Oncology, vol. 123, no. 2, pp. 189-194 . https://doi.org/10.1016/j.radonc.2017.02.006
Radiotherapy and Oncology, 123(2), 189-194. Elsevier Ireland Ltd
Radiotherapy and Oncology, 123(2), 189-194. Elsevier Ireland Ltd
Introduction: Commonly used clinical models for survival prediction after stereotactic radiosurgery (SRS) for brain metastases (BMs) are limited by the lack of individual risk scores and disproportionate prognostic groups. In this study, two nomogram
Publikováno v:
Cancers, 11(6):782. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Volume 11
Issue 6
Cancers, Vol 11, Iss 6, p 782 (2019)
Cancers
Volume 11
Issue 6
Cancers, Vol 11, Iss 6, p 782 (2019)
Purpose: Combining reirradiation (reRT) with hyperthermia (HT) has shown to be of high therapeutic value for patients with loco-regionally recurrent breast cancer. The purpose of this study was to compare the long-term therapeutic effect and toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46fcd036191a39ec37f6b9bcaa772102
https://pure.amc.nl/en/publications/impact-of-technique-and-schedule-of-reirradiation-plus-hyperthermia-on-outcome-after-surgery-for-patients-with-recurrent-breast-cancer(2f0f0bb3-017a-4c94-885e-a3913289d47e).html
https://pure.amc.nl/en/publications/impact-of-technique-and-schedule-of-reirradiation-plus-hyperthermia-on-outcome-after-surgery-for-patients-with-recurrent-breast-cancer(2f0f0bb3-017a-4c94-885e-a3913289d47e).html
Autor:
Vrieling, C, Collette, L, Fourquet, A, Hoogenraad, W.J, Horiot, J.-C, Jager, J.J, Bing Oei, S, Peterse, H.L, Pierart, M, Poortmans, P.M, Struikmans, H, Van den Bogaert, W, Bartelink, H
Publikováno v:
In European Journal of Cancer May 2003 39(7):932-944
Autor:
S. Oldenborg, Hans Crezee, Bing Oei, Jack L.M. Venselaar, Martijn W. Heymans, Y. Kusumanto, Geertjan van Tienhoven, Paul J. Zum Vörde Sive Vörding, Coen R. N. Rasch, Rob M. van Os
Publikováno v:
Oldenborg, S, Rasch, C R N, van Os, R, Kusumanto, Y H, Oei, B S, Venselaar, J L, Heymans, M W, Zum Vörde Sive Vörding, P J, Crezee, H & van Tienhoven, G 2018, ' Rebestrahlung + Hyperthermie bei Brustkrebs in Form von Cancer en cuirasse ', Strahlentherapie und Onkologie, vol. 194, no. 3, pp. 206-214 . https://doi.org/10.1007/s00066-017-1241-7
Strahlentherapie und Onkologie, 194(3), 206-214. SPRINGER HEIDELBERG
Strahlentherapie Und Onkologie
Strahlentherapie und Onkologie, 194(3), 206-214. SPRINGER HEIDELBERG
Strahlentherapie Und Onkologie
Background and purpose Patients with irresectable locoregional recurrent breast cancer en cuirasse (BCEC) do not have effective curative treatment options. Hyperthermia, the elevation of tumor temperature to 40–45 °C, is a well-established radio-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84742f0301a90f02ff4507a5472b97ec
https://research.vumc.nl/en/publications/85072b47-cf52-4753-b929-908c2bddbf66
https://research.vumc.nl/en/publications/85072b47-cf52-4753-b929-908c2bddbf66
Autor:
Bing Oei, S. Oldenborg, Martijn W. Heymans, Hans Crezee, Y. Kusumanto, Coen R. N. Rasch, Jack L.M. Venselaar, M.W. Kolff, Rob M. van Os, Geertjan van Tienhoven, V. Griesdoorn, Paul J. Zum Vörde Sive Vörding
Publikováno v:
Oldenborg, S, Griesdoorn, V, van Os, R, Kusumanto, Y H, Oei, B S, Venselaar, J L, Zum Vörde Sive Vörding, P J, Heymans, M W, Kolff, M W, Rasch, C R N, Crezee, H & van Tienhoven, G J 2015, ' Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters ', Radiotherapy and Oncology, vol. 117, no. 2, pp. 223-228 . https://doi.org/10.1016/j.radonc.2015.10.017
Radiotherapy and Oncology, 117(2), 223-228. Elsevier Ireland Ltd
Radiotherapy and Oncology, 117(2), 223-228. ELSEVIER IRELAND LTD
Radiotherapy and oncology, 117(2), 223-228. Elsevier Ireland Ltd
Radiotherapy and Oncology, 117(2), 223-228. Elsevier Ireland Ltd
Radiotherapy and Oncology, 117(2), 223-228. ELSEVIER IRELAND LTD
Radiotherapy and oncology, 117(2), 223-228. Elsevier Ireland Ltd
Background/purpose: Treatment options for irresectable locoregional recurrent breast cancer in previously irradiated area are limited. Hyperthermia, elevating tumor temperature to 40-45 degrees C, sensitizes radio-and-chemotherapy. Four hundred and f
Autor:
Harry, Bartelink, Philippe, Maingon, Philip, Poortmans, Caroline, Weltens, Alain, Fourquet, Jos, Jager, Dominic, Schinagl, Bing, Oei, Carla, Rodenhuis, Jean-Claude, Horiot, Henk, Struikmans, Erik, Van Limbergen, Youlia, Kirova, Paula, Elkhuizen, Rudolf, Bongartz, Raymond, Miralbell, David, Morgan, Jean-Bernard, Dubois, Vincent, Remouchamps, René-Olivier, Mirimanoff, Sandra, Collette, Laurence, Collette, F, Kovner
Publikováno v:
Lancet Oncology, 16, 1, pp. 47-56
Lancet Oncology, 16, 47-56
Lancet oncology, 16(1), 47-56. Elsevier Science
LANCET ONCOLOGY, 16(1), 47. Lancet Publishing Group
The Lancet Oncology, Vol. 16, No 1 (2015) pp. 47-56
Lancet Oncology, 16, 47-56
Lancet oncology, 16(1), 47-56. Elsevier Science
LANCET ONCOLOGY, 16(1), 47. Lancet Publishing Group
The Lancet Oncology, Vol. 16, No 1 (2015) pp. 47-56
Item does not contain fulltext BACKGROUND: Since the introduction of breast-conserving treatment, various radiation doses after lumpectomy have been used. In a phase 3 randomised controlled trial, we investigated the effect of a radiation boost of 16
Autor:
Dominic A.X. Schinagl, Guus Hart, Alain Fourquet, Harry Bartelink, Paula H.M. Elkhuizen, Philip Poortmans, Jean-Claude Horiot, Youlia M. Kirova, Raymond Miralbell, Vincent Remouchamps, Laurence Collette, Erik van Werkhoven, René-Olivier Mirimanoff, Philippe Maingon, D.A.L. Morgan, Rudolf Bongartz, Carla C. Rodenhuis, Conny Vrieling, Bing Oei, Henk Struikmans, Sandra Collette, Caroline Weltens, Jean-Bernard Dubois, Erik Van Limbergen
Publikováno v:
JAMA Oncology, Vol. 3, No 1 (2017) pp. 42-48
Jama Oncology, 3, 42-48
Jama Oncology, 3, 1, pp. 42-48
Jama Oncology, 3, 42-48
Jama Oncology, 3, 1, pp. 42-48
Item does not contain fulltext Importance: Prognostic factors of ipsilateral breast tumor recurrence (IBTR) may change over time following breast-conserving therapy. Objective: The EORTC "boost no boost" trial showed that young age and high-grade inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18758c8080419ed4bc4ddc5344b37bce
https://archive-ouverte.unige.ch/unige:100678
https://archive-ouverte.unige.ch/unige:100678
Autor:
Jos A. Stigt, R. Wijsman, José Belderbos, Anita J. W. M. Brouns, Dirk De Ruysscher, Gerben Bootsma, Bonne Biesma, S. Bing Oei, Jan Bussink, Anne-Marie C. Dingemans, Michel M. van den Heuvel, Lizza E.L. Hendriks, Mohammad Amini, Wilma Uyterlinde
Publikováno v:
Lung Cancer, 101, pp. 68-75
Lung Cancer, 101, 68-75. Elsevier Ireland Ltd
Lung Cancer, 101, 68-75
Lung Cancer, 101, 68-75. Elsevier Ireland Ltd
Lung Cancer, 101, 68-75
Contains fulltext : 165952.pdf (Publisher’s version ) (Open Access) OBJECTIVES: Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b740b20289b3480a43bc4af2632d17dd
https://hdl.handle.net/2066/165952
https://hdl.handle.net/2066/165952